GlassScriptPhysician profile
Ronald W Kennett
NPI 1154318996
$2,611.76
in general payments reported to CMS, 2019-2025
31 companies · $336 in 2025
The $336 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $460 · 2020: $72.97 · 2021: $317 · 2022: $324 · 2023: $493 · 2024: $609 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,438.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $521.33 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $286.12 | 2019 | |
| Glaxosmithkline, LLC. | $190.01 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $172.58 | 2024 | Veozah |
| Abbott Laboratories | $126.56 | 2019-2023 | Freestyle Libre 2 |
| Pfizer INC. | $124.54 | 2021-2024 | |
| Eisai INC. | $101.36 | 2024-2025 | |
| Lilly USA, LLC | $92.73 | 2024-2025 | Mounjaro, Zepbound, Trulicity |
| Novartis Pharmaceuticals Corporation | $89.09 | 2019-2023 | |
| Abiomed | $85.13 | 2019-2023 | Impella |
| Medtronic, INC. | $65.69 | 2022-2025 | Synchromedii, Intellis Adaptivestim |
| Phadia US INC. | $64.79 | 2023-2024 | Immunocap |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.35 | 2021-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $61.14 | 2020-2024 | Airsupra |
| Amgen INC. | $60.06 | 2021-2024 | Repatha, Otezla |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $54.42 | 2023-2024 | Inspire |
| Lucid Diagnostics INC. | $47.02 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $45.64 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $45.07 | 2022 | |
| Merck Sharp & Dohme LLC | $39.84 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $38.13 | 2023 | |
| Viiv Healthcare Company | $37.13 | 2023 | Apretude |
| Arbor Pharmaceuticals, INC. | $34.61 | 2021-2022 | |
| Abbvie INC. | $28.87 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.54 | 2021 | |
| Corcept Therapeutics | $25.15 | 2025 | Korlym |
| Phathom Pharmaceuticals, INC. | $22.83 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.61 | 2021 | |
| Vistapharm, INC. | $12.53 | 2021 | |
| Paratek Pharmaceuticals, INC. | $12.14 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.75 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Kennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.